DiscoverPeerVoice Oncology & Haematology VideoAna Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice
Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Update: 2024-11-08
Share

Description

Visit https://www.peervoice.com/JQU860 to view the entire programme with slides. After completing “Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice”, participants will be able to: Recognise the role of HER2 as a target in cancer sites beyond breast and gastric; Explain the HER2 testing and scoring recommendations for gynaecological cancers; Summarise the clinical evidence for emerging HER2-directed therapies for HER2-positive gynaecological cancers; and Evaluate and manage the safety profile for emerging HER2-directed therapies for HER2-positive gynaecological cancers.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

PeerVoice